Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SOD1


Brief Information

Name:Superoxide dismutase
Target Synonym:SOD1,Superoxide Dismutase 1,HSod1,Amyotrophic Lateral Sclerosis 1 (Adult),Epididymis Secretory Protein Li 44,Superoxide Dismutase [Cu-Zn],Cu/Zn Superoxide Dismutase,Indophenoloxidase A,SOD, Soluble,EC,HEL-S-44,IPOA,ALS1,SOD,ALS,Superoxide Dismutase,STAHP,EC:,Superoxide Dismutase 1, Soluble,Superoxide Dismutase, Cystolic,Homodimer
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
SO1-H5148 Human Human SOD1 / Cu-Zn SOD Protein, His Tag (active enzyme)
ACRO Quality

Synonym Name

SOD1,Superoxide dismutase 1,hSod1


Superoxide dismutase [Cu-Zn] (SOD1) is also known as superoxide dismutase 1 (hSod1), an enzyme that in humans is encoded by the SOD1 gene, located on chromosome 21. SOD1 can bind copper and zinc ions and is one of three superoxide dismutases responsible for destroying free superoxide radicals in the body. The encoded isozyme (SOD1) is a soluble cytoplasmic and mitochondrial intermembrane space protein, acting as a homodimer to convert naturally occurring, but harmful, superoxide radicals to molecular oxygen and hydrogen peroxide. Furthermore, the mutations of SOD1 gene can result in a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Orgotein Approved Gt Biopharma Inc Ontosein Spain Rheumatic Diseases; Cystitis; Radiation Injuries null 1996-01-01 Cystitis; Radiation Injuries; Rheumatic Diseases Details
Tofersen 99mTc-MAG3-BIIB067; ISIS-333611; BIIB-067 Approved Ionis Pharmaceuticals Inc, Ludwig Institute For Cancer Research QALSODY United States Amyotrophic Lateral Sclerosis Biogen Ma Inc, Biogen Inc 2023-04-25 Amyotrophic Lateral Sclerosis Details
Cupric Sulfate/Manganese sulfate/Selenious acid/Zinc Sulfate Approved American Regent Inc MULTRYS United States Dietary Supplement American Regent Inc 2020-07-02 Dietary Supplement Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NI-005 AP-101 (AL-S Pharma); NI-005 Phase 1 Clinical Al-S Pharma Ag Amyotrophic Lateral Sclerosis Details
Otaplimastat SP-8203 hydrochloride; SP8203 HCL; SP-8203 Phase 2 Clinical Shin Poong Pharmaceutical Co Ltd Stroke Details
APB-102 APB-102; AMT-162 Phase 2 Clinical University Of Massachusetts Medical School Amyotrophic Lateral Sclerosis Details
ARO-SOD1 ARO-SOD1; ARO-SOD-1 Phase 1 Clinical Arrowhead Pharmaceuticals Inc Amyotrophic Lateral Sclerosis Details
BMX-010 BMX-010; MnTE-2-PyP; MnTE-2-PyP5+ Phase 2 Clinical Duke University Acne Vulgaris; Rosacea; Psoriasis; Dermatitis, Atopic Details
NAS150 AEOL-10150; NAS150; NAS-150 Phase 1 Clinical Aeolus Pharmaceuticals Supranuclear Palsy, Progressive; Idiopathic Pulmonary Fibrosis; Neoplasms; Lung Injury Details
Bis-choline tetrathiomolybdate ATN-224; WTX-101; ALXN-1840 Phase 1 Clinical Wilson Therapeutics Hepatolenticular Degeneration; Multiple Myeloma; Prostatic Neoplasms; Melanoma Details
Superoxide dismutase (Ube Industries) r-hSOD; FKU-871 Phase 2 Clinical Ube Industries Ltd, Astellas Pharma Inc Myocardial Ischemia; Diabetic Neuropathies Details
Rucosopasem manganese GC-4711 Phase 1 Clinical Galera Therapeutics Inc Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message